

## Curriculum Vitae

<b>Name</b>	<b>Jeong Il Yu</b>	
<b>Current Position &amp; Affiliation</b>	<b>Assistant Professor Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</b>	
<b>Country</b>	<b>Korea, Republic of</b>	

### Educational Background

1999~2005	MD at CHA University, College of Medicine (former School of Medicine, Pocheon Cha University)
2008~2012	Master's course and a degree The graduate school, Chungbuk National University
2012~2017	Ph.D.'s course and a degree The graduate school, Sungkyunkwan University

### Professional Experience

2010~2013	Public health Doctor Yoncheon-gun Medical Center, Gyonggi-do, Korea (2010-2012) Gwangju-si, Gyonggi-do, Korea (2012-2013)
2013~2015	Clinical fellow, Department of Radiation Oncology, Samsung Medical Center, Seoul
2015~2016	Instructor, Department of Radiation Oncology, Samsung Medical Center, Seoul
2016~2018	Clinical Assistant Professor, Department of Radiation Oncology, Samsung Medical Center, Seoul
2019~	Assistant Professor, Department of Radiation Oncology, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul

## Professional Organizations

2005.3	Member, Korean Medical Association (KMA)
2010.3	Member, Korean Society for Radiation Oncology (KOSRO)
2013.5	Member, Korean Cancer Association (KCA)
2013.5	Member, Korean Society of Medical Oncology (KSMO)
2013.5	Member, The Korean Liver Cancer Study Group (KLCSG)

## Main Scientific Publications

- [1] Baek JY, Yu JI, Park HC, Choi DH, Yoo GS, Lee WY, et al. Determining whether postoperative chemoradiotherapy is required in patients with pathologic t3n0 rectal cancer with negative resection margin. *Int J Colorectal Dis* 2020;35(12):2239-48.
- [2] Cho WK, Yu JI, Park HC, Lim DH, Kim TH, Chie EK. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. *Tumori* 2020:300891620937795.
- [3] Kim N, Yu JI, Park HC, Yoo GS, Choi C, Hong JY, et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. *Cancer Immunol Immunother* 2020.
- [4] Park JS, Yu JI, Lim DH, Nam H, Kim YI, Lee J, et al. Impact of radiotherapy on kidney function among patients who received adjuvant treatment for gastric cancer: Logistic and linear regression analyses. *Cancers (Basel)* 2020;13(1).
- [5] Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, et al. A randomized phase iii trial comparing adjuvant single-agent s1, s-1 with oxaliplatin, and postoperative chemoradiation with s-1 and oxaliplatin in patients with node-positive gastric cancer after d2 resection: The artist 2 trial. *Ann Oncol* 2020.
- [6] Yoo GS, Park HC, Yu JI, Choi DH, Cho WK, Park YS, et al. Carcinoembryonic antigen improves the performance of magnetic resonance imaging in the prediction of pathologic response after neoadjuvant chemoradiation for patients with rectal cancer. *Cancer Res Treat* 2020;52(2):446-54.
- [7] Yoo GS, Yu JI, Cho S, Jung SH, Han Y, Park S, et al. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. *Radiother Oncol* 2020;146:187-93.
- [8] Yoo GS, Yu JI, Park HC, Hyun D, Jeong WK, Lim HY, et al. Do biliary complications after proton beam therapy for perihilar hepatocellular carcinoma matter? *Cancers (Basel)* 2020;12(9).

- [9] Yu JI, Choi C, Lee J, Kang WK, Park SH, Kim ST, et al. Effect of baseline sarcopenia on adjuvant treatment for d2 dissected gastric cancer: Analysis of the artist phase iii trial. *Radiother Oncol* 2020;152:19-25.
- [10] Yu JI, Park HC, Lee J, Choi C, Kang WK, Park SH, et al. Outcomes of radiotherapy for mesenchymal and non-mesenchymal subtypes of gastric cancer. *Cancers (Basel)* 2020;12(4).
- [11] Yu JI, Park HC, Yoo GS, Paik SW, Choi MS, Kim HS, et al. Clinical significance of systemic inflammation markers in newly diagnosed, previously untreated hepatocellular carcinoma. *Cancers (Basel)* 2020;12(5).
-